Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

S6826

Sigma-Aldrich

Stiripentol

≥98% (HPLC)

Sinónimos:

4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol, Diacomit

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C14H18O3
Número de CAS:
49763-96-4
Peso molecular:
234.29
EC Number:
256-480-9
MDL number:
MFCD00869310
UNSPSC Code:
12352200
PubChem Substance ID:
329824570
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: ≥20 mg/mL

storage temp.

−20°C

SMILES string

CC(C)(C)C(O)\C=C\c1ccc2OCOc2c1

InChI

1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+

InChI key

IBLNKMRFIPWSOY-FNORWQNLSA-N

Application

Stiripentol has been used in pharmacokinetic analysis and as a reference standard in fluorescence spectra analysis.
Stiripentol may be used in GABAA receptor-mediated cell signaling studies.

Biochem/physiol Actions

Anti-convulsant drug

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000348788
0000348978
0000245715
0000251477
0000251475

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

C Chiron et al.
Lancet (London, England), 356(9242), 1638-1642 (2000-11-23)
Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a
Screening of conventional anticonvulsants in a genetic mouse model of epilepsy.
Hawkins NA, et al.
Annals of Clinical and Translational Neurology, 4(5), 326-339 (2017)
Carole Giraud et al.
Drug metabolism and disposition: the biological fate of chemicals, 34(4), 608-611 (2006-01-18)
A metabolic interaction between stiripentol (STP), an anticonvulsant agent that inhibits the activity of several cytochromes P450 (P450s), and clobazam (CLB), a 1,5-benzodiazepine, used in association with STP in severe myoclonic epilepsy in infancy was observed in vivo. This interaction
Behrouz Kassaï et al.
Epilepsia, 49(2), 343-348 (2007-11-22)
Severe myoclonic epilepsy in infancy (SMEI) is a rare, but severe disorder with seizures typically resistant to conventional antiepileptic drugs. The objective of the present study was to systematically review the literature on the available treatments for SMEI. Databases searched
M Bebin et al.
Drugs, 48(2), 153-171 (1994-08-01)
In the past decade, several new antiepileptic drugs have been tested. Most recently, 5 new antiepileptic drugs have been launched onto European and US markets. These include vigabatrin, oxcarbazepine and lamotrigine in Europe, and felbamate and gabapentin in the US.
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico